Table 2.
Concentrations of analytes in plasma and five consecutive CSF fractions
| N | 20 | 20 | 20 | 20 | 20 | 20 | p-value | F (df, error df) | χ2 (df) |
|---|---|---|---|---|---|---|---|---|---|
| Plasma | CSF 0–2 mL | CSF 2–4 mL | CSF 4–6 mL | CSF 6–8 mL | CSF 8–10 mL | ||||
| Monoamines, precursors and metabolites | |||||||||
| L-DOPA (nmol/L) | 17.0 [14.1–31.4] | 5.44 (4.75–6.13) | 5.37 (4.64–6.10) | 5.20 (4.55–5.84) | 5.55 (4.65–6.46) | 5.26 (4.51–6.01) | 0.426 | 0.93 (4, 76) | |
| 3-OMD (nmol/L) | 96.4 (84.5–108.3) | 13.3 [10.6–16.2] | 12.8 [10.4–17.0] | 12.8 [10.3–16.5] | 12.6 [10.7–16.0] | 12.9 [10.8–15.3] | 0.981 | 0.41 (4) | |
| DA (nmol/L) | 0.09 (0.08–0.11) | 0.031 [0.020–0.054] | 0.035 [0.025–0.052] | 0.040 [0.026–0.059] | 0.047 [0.030–0.056] | 0.050 [0.037–0.063] | < 0.001*** | 42.12 (4) | |
| DOPAC (nmol/L) | 9.61 (7.24–11.99) | 2.60 (2.20–3.00) | 2.80 2.35–3.24) | 2.96 (2.49–3.44) | 3.11 (2.60–3.62) | 3.28 (2.77–3.79) | < 0.001*** | 18.5 (1.85, 35.10) | |
| 3-MT (nmol/L) | 0.02 (0.06–0.05) | 0.016 [0.011–0.029] | 0.018 [0.012–0.035] | 0.022 [0.016–0.039] | 0.028 [0.017–0.050] | 0.031 [0.022–0.056] | < 0.001*** | 38.3 (4) | |
| HVA (nmol/L) | 69.6 (58.8–80.3) | 211 (175–246) | 225 (188–262) | 245 (205–285) | 260 (218–302) | 272 (230–314) | < 0.001*** | 28.1 (1.60, 30.4) | |
| NA (nmol/L) | 2.54 (0.82–1.30) | 0.81 [0.58–0.91] | 0.76 [0.62–0.90] | 0.80 [0.64–1.01] | 0.81 [0.67–1.04] | 0.88 [0.70–1.13] | < 0.001*** | 39.8 (4) | |
| NMN (nmol/L) | 0.40 [0.35–0.47] | 0.37 [0.26–0.41] | 0.42 [0.26–0.47] | 0.44 [0.28–0.49] | 0.38 [0.28–0.53] | 0.46 [0.32–0.55] | < 0.001*** | 42.937 (4) | |
| MOPEG (nmol/L) | 22.2 (19.7–24.6) | 47.7 (44.6–50.9) | 48.2 (44.8–51.5) | 48.8 (44.8–52.8) | 49.5 (45.8–53.3) | 50.1 46.7–53.5) | 0.054 | 2.44 (4, 76) | |
| ADR (nmol/L) | 0.23 [0.15–0.43] | ND | ND | ND | ND | ND | |||
| MN (nmol/L) | 0.23 (0.18–0.28) | ND | ND | ND | ND | ND | |||
| 5-HIAA (nmol/L) | 50.2 (44.3–56.1) | 101.1 (84.4–117.8) | 111.9 (95.2–128.5) | 124.4 (106.4–142.3) | 130.3 (111.7–149.0) | 136.7 (118.5–154.8) | < 0.001*** | 24.0 (1.57, 29.91) | |
| Routine laboratory analysis | |||||||||
| Albumin (g/L) | 45.3 (43.3–47.2) | 0.21 (0.18–0.25) | 0.20 (0.17–0.24) | 0.20 (0.17–0.20) | 0.19 (0.15–0.22) | 0.19 (0.15–0.22) | < 0.001*** | 16.936 (2.003, 38.054) | |
| Qalb (× 10–3) | – | 4.73 (3.97–5.50) | 4.54 (3.76–5.32) | 4.42 (3.68–5.16) | 4.13 (3.41–4.86) | 4.15 (3.40–4.89) | |||
| Total protein (g/L) | 73.3 (70.6–75.9) | 0.34 (0.30–0.39) | 0.33 (0.29–0.38) | 0.33 (0.28–0.37) | 0.31 (0.27–0.36) | 0.31 (0.26–0.36) | < 0.001*** | 11.393 (1.816, 34.509) | |
| Glucose (mmol/L) | 5.25 (4.96–5.54) | 3.31 (3.18–3.43) | 3.34 (3.21–3.47) | 3.33 (3.20–3.45) | 3.34 (3.20–3.47) | 3.33 (3.20–3.46) | 0.047* | 2.536 (4, 76) | |
| Erythrocyte count (× 106/L) | – | 200 [100–300] | 150 [100–275] | 100 [100–200] | 100 [100–200] | 100 [100–200] | 0.083 | 8.230 (4) | |
| Leucocyte count (× 106/L) | 5.95 (5.49–6.93) | 1.00 [1.00–2.75] | 1.00 [1.00–1.75] | 1.00 [1.00–1.75] | 1.00 [0.25–2.00] | 1.00 [0.00–1.00] | 0.001** | 19.551 (4) | |
Data are presented as mean (95% CI) or median [IQR]. Test (repeated-measures ANOVA or Friedman’s test) is significant at 0.05 level (*), 0.01 level (**) or 0.001 level (***)
L-DOPA levodopa, 3-OMD 3-o-methyldopa, DA dopamine, DOPAC 3,4-Dihydroxyphenylacetic acid, 3-MT 3-methoxytyramine, HVA homovanillic acid, NA noradrenalin, NMN normetanephrine, ADR adrenalin, MN metanephrine, MOPEG 3-Methoxy-4-hydroxyphenylglycol, 5-HIAA 5-hydroxyindoleacetic acid, Qalb ratio of CSF to plasma albumin concentration, ND non-detectable, df degrees of freedom